Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuronetics (STIM) Cash from Investing Activities (2017 - 2025)

Neuronetics (STIM) has disclosed Cash from Investing Activities for 9 consecutive years, with -$114000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities fell 914.29% to -$114000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.0 million, a 393.5% decrease, with the full-year FY2024 number at -$2.4 million, down 82.53% from a year prior.
  • Cash from Investing Activities was -$114000.0 for Q3 2025 at Neuronetics, up from -$252000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $9.3 million in Q3 2022 to a low of -$7.9 million in Q3 2021.
  • A 5-year average of -$390947.4 and a median of -$433000.0 in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 5953.44% in 2021, then soared 216.95% in 2022.
  • Neuronetics' Cash from Investing Activities stood at -$801000.0 in 2021, then skyrocketed by 37.2% to -$503000.0 in 2022, then dropped by 11.93% to -$563000.0 in 2023, then plummeted by 322.02% to -$2.4 million in 2024, then soared by 95.2% to -$114000.0 in 2025.
  • Per Business Quant, the three most recent readings for STIM's Cash from Investing Activities are -$114000.0 (Q3 2025), -$252000.0 (Q2 2025), and -$219000.0 (Q1 2025).